FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

ClinicalTrials.gov ID: NCT05614739

Public ClinicalTrials.gov record NCT05614739. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.

Study identification

NCT ID: NCT05614739
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 677 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 11, 2023
Primary completion: May 31, 2027
Completion: May 31, 2027
Last update posted: Aug 19, 2026

2023 – 2027

United States locations

U.S. sites: 41
U.S. states: 21
U.S. cities: 32

Facility	City	State	ZIP	Site status
University of Arizona - Cancer Center	Tucson	Arizona	85719	Recruiting
City of Hope	Duarte	California	91010	Recruiting
University of California, Los Angeles (UCLA) - Division of Hematology-Oncology	Los Angeles	California	90095	Recruiting
University of California - Irvine	Orange	California	92868	Recruiting
University of California (UC) Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
Stanford Medicine Cancer Center	Stanford	California	94305	Recruiting
Advent Health	Orlando	Florida	32804	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
The University of Chicago Medical Center (UCMC)	Chicago	Illinois	60637	Recruiting
Indiana University (IU) Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	46202	Recruiting
Mary Bird Perkins Cancer Center	Baton Rouge	Louisiana	70809	Recruiting
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	Recruiting
Johns Hopkins Kimmel Cancer Center	Baltimore	Maryland	21231-2410	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Washington University in St. Louis	St Louis	Missouri	63108	Recruiting
New York University (NYU)	New York	New York	10016	Recruiting
Weill Cornell Medicine	New York	New York	10021	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Columbia University	New York	New York	10032	Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University of Rochester - Wilmot Cancer Institute	Rochester	New York	14642	Recruiting
Montefiore Medical Center	The Bronx	New York	10467	Recruiting
University of North Carolina (UNC) - Chapel Hill	Chapel Hill	North Carolina	27599	Recruiting
University of Cincinnati Medical Center (UCMC)	Cincinnati	Ohio	45267	Recruiting
The Ohio State University (OSU)	Columbus	Ohio	43210	Recruiting
University of Oklahoma - Health Sciences Center	Oklahoma City	Oklahoma	73104	Recruiting
Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute	Lancaster	Pennsylvania	17601	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	Recruiting
Allegheny General Hospital	Pittsburgh	Pennsylvania	15212	Recruiting
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15213	Recruiting
Carolina Urologic Research Center	Myrtle Beach	South Carolina	29572	Recruiting
Sarah Cannon and HCA Research Institute	Nashville	Tennessee	37203	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37212	Recruiting
University of Texas Southwestern	Dallas	Texas	75244	Recruiting
Texas Oncology, P.A	Dallas	Texas	75251	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Utah	Salt Lake City	Utah	84132	Recruiting
University of Vermont Medical Center	Burlington	Vermont	05401	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05614739, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 19, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05614739 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →